These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 7818264

  • 21. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT.
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [Abstract] [Full Text] [Related]

  • 22. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

  • 23. Long-term experience with selegiline and levodopa in Parkinson's disease.
    Lieberman A.
    Neurology; 1992 Apr; 42(4 Suppl 4):32-6; discussion 41-8. PubMed ID: 1584430
    [Abstract] [Full Text] [Related]

  • 24. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [Abstract] [Full Text] [Related]

  • 25. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P, Oakes D, Cui L.
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [Abstract] [Full Text] [Related]

  • 26. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK, Verma S, Cordingley GJ, Harris RI.
    Pharmatherapeutica; 1985 Mar; 4(2):132-40. PubMed ID: 4059292
    [Abstract] [Full Text] [Related]

  • 27. [Daily defined doses of parkinsonian drugs in Alcoi].
    Manzanares R, Matías-Guiu J, Provencio R, Falip R, López-Arlandis J, Martín R, Ruiz C.
    Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
    [Abstract] [Full Text] [Related]

  • 28. New concepts in the treatment of Parkinson's disease.
    Ahlskog JE, Wilkinson JM.
    Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Sinemet CR in Parkinson's disease.
    Pfeiffer RF, Wilken KE, Glaeske CS, Hofman R.
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias.
    Mark MH, Sage JI.
    Ann Clin Lab Sci; 1994 Jan; 24(1):12-21. PubMed ID: 8147565
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.